Full name
Observational, Long-term Safety and Tolerability Study (LLSAT) of Linerixibat in Adults with PBC and moderate to severe itch
NCT Number
NCT04167358
Geography
US
Non-US
Locations
Argentina, Belgium, Brazil, Bulgaria, Canada, China, Czechia, France, Germany, Greece, Israel, Italy, Japan, Mexico, Poland, Russian Federation, Spain, Switzerland, United States
Primary Endpoints
- Number of participants with non-serious adverse events (AEs) and Serious AEs (SAEs). Up to 66 months
- Number of participants with Severe AEs. Up to 66 months
External Link
https://clinicaltrials.gov/study/NCT04167358
Order
1
Disease
Version
Phase
3